<p>2025 年 9 月 11 日- 上午 7:42</p>
<p>佛罗里达州西棕榈滩，2025 年 9 月 11 日（GLOBE NEWSWIRE）-- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>（“公司”）宣布已签署股票购买协议，以收购 Vector Biosource Inc.（“Vector”）。Vector 是一家为生物技术、临床研究和制药研究行业提供信息、数据和生物样本来源的供应商。Vector 在 2025 年第二季度的净收入约为 225,000 美元（按年化计算为 90 万美元），预计在收购后将显著增长。</p>
<p>预计购买价格包括：（i）50 万美元现金，（ii）60,000 股公司的 E 系列累积可赎回优先股（“E 系列优先股”）（面值 150 万美元），（iii）以比收盘价高 10% 的溢价购买 200 万美元公司普通股的认股权证，以及（iv）最多额外 80,000 股 E 系列优先股（面值最多 200 万美元），这取决于在未来 12 到 24 个月内实现某些收入和现金回收里程碑。预计在满足多项成交条件后尽快完成交易，包括但不限于尽职调查的完成和认股权证及雇佣协议的最终确定。此外，FOXO 已同意为 Vector 的增长计划提供最多 120 万美元的资金。有关 Vector Biosource 的信息可以在 www.vectorbiosource.com 找到。</p>
<p>“我们很高兴与 Vector 达成协议，推进这一战略收购，” FOXO 首席执行官 Seamus Lagan 表示。“我们被 Vector 在医疗服务领域的地位、其商业基本面和增长前景所吸引，并打算与 Vector 的高级领导层紧密合作，通过有机增长和潜在收购积极扩展 Vector。” Vector 的首席执行官 Frank Dias, Jr.解释道：“我们相信与 FOXO 的合作将使 Vector 能够通过提供增长资金、企业基础设施和与其他 FOXO 子公司的潜在协同效应，实现其近期和长期的增长计划。”</p>
<p>本新闻稿不构成出售任何证券的要约或购买任何证券的要约邀请。任何要约、购买要约的邀请或任何证券的销售将根据《1933 年证券法》（修订版）（“证券法”）的注册要求进行。本公告是根据证券法第 135 条发布的。</p>
<p><strong>关于 FOXO Technologies Inc.（“FOXO”）</strong></p>
<p>FOXO 拥有并运营三家子公司。</p>
<p>Rennova Community Health, Inc.拥有并运营 Scott County Community Hospital, Inc.（以 Big South Fork Medical Center 为名），这是位于东田纳西州的一家关键接入医院（CAH）。</p>
<p>Myrtle Recovery Centers, Inc.是一家位于东田纳西州的 30 床位行为健康设施。Myrtle 提供住院戒毒和住院治疗服务，以及 MAT 和 OBOT 项目的门诊服务。</p>
<p>FOXO Labs, Inc.是一家生物技术公司，致力于通过开发尖端技术和产品解决方案来改善人类健康和寿命，服务于各个行业。</p>
<p>有关 FOXO 的更多信息，请访问 www.foxotechnologies.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。这些声明是在 1995 年美国私人证券诉讼改革法的 “安全港” 条款下作出的。非历史事实的声明，包括关于 FOXO 的信念和期望的声明，均为前瞻性声明。前瞻性声明涉及固有的风险和不确定性，许多因素可能导致实际结果与任何前瞻性声明中包含的结果有重大差异。这些因素包括但不限于 FOXO 所处的竞争激烈且高度监管的行业中变化的风险；竞争对手之间的运营表现差异或影响 FOXO 业务的法律法规变化；实施 FOXO 的商业计划、预测和其他期望的能力；获得融资的能力；FOXO 有亏损历史，未来可能无法实现或维持盈利的风险；FOXO 的知识产权的可执行性，包括其专利，以及可能侵犯他人知识产权的风险；以及 FOXO 所处的高度竞争行业中经济下滑和监管环境变化的风险。上述因素的清单并不详尽。读者应仔细考虑上述因素以及 FOXO 最近在 10-K 和 10-Q 表格中讨论的其他风险和不确定性，特别是这些报告的 “风险因素” 部分，以及 FOXO 已提交或将提交给 SEC 的其他文件。这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大差异的其他重要风险和不确定性。前瞻性声明仅在作出之日有效。读者被警告不要过度依赖前瞻性声明，FOXO 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>联系方式：</strong></p>
<p>Sebastien Sainsbury</p>
<p>ssainsbury@foxotechnologies.com</p>
<p>(561) 485-0151</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png"/></p>

FOXO

<p>FOXO Technologies Inc. 已签署股票购买协议，以现金、60,000 股 E 系列优先股和价值 200 万美元的普通股认股权证，总预计购买价格为 500,000 美元收购 Vector Biosource Inc.。Vector 在 2025 年第二季度的净收入约为 225,000 美元，预计收购后将显著增长。FOXO 计划为 Vector 的增长计划提供高达 120 万美元的支持。这笔收购被视为增强 FOXO 在医疗服务领域地位的战略举措</p>

<p>09/11/2025 - 07:42 AM</p>
<div class="lb-trans"><p>2025 年 9 月 11 日- 上午 7:42</p>
</div><p>WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>(the “Company”), announces that it has signed a stock purchase agreement to acquire Vector Biosource Inc. (“Vector”). Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 ($0.9 million on an annual run rate basis) and is expected to grow significantly post-acquisition.</p>
<div class="lb-trans"><p>佛罗里达州西棕榈滩，2025 年 9 月 11 日（GLOBE NEWSWIRE）-- <strong>FOXO Technologies Inc.(OTC:FOXO)</strong>（“公司”）宣布已签署股票购买协议，以收购 Vector Biosource Inc.（“Vector”）。Vector 是一家为生物技术、临床研究和制药研究行业提供信息、数据和生物样本来源的供应商。Vector 在 2025 年第二季度的净收入约为 225,000 美元（按年化计算为 90 万美元），预计在收购后将显著增长。</p>
</div><p>The expected purchase price consists of: (i) $500,000 in cash, (ii) 60,000 shares of the Company’s Series E Cumulative Redeemable Secured Preferred Stock (the “Series E Preferred Stock”) ($1.5 million in stated value), (iii) warrants to purchase $2 million of the Company’s common stock at a 10% premium to the common stock’s closing price one day prior to closing, and (iv) up to an additional 80,000 shares of Series E Preferred Stock (up to $2.0 million in stated value) subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO has agreed to fund up to $1.2 million of Vector’s growth initiatives. Information on Vector Biosource can be found at www.vectorbiosource.com</p>
<div class="lb-trans"><p>预计购买价格包括：（i）50 万美元现金，（ii）60,000 股公司的 E 系列累积可赎回优先股（“E 系列优先股”）（面值 150 万美元），（iii）以比收盘价高 10% 的溢价购买 200 万美元公司普通股的认股权证，以及（iv）最多额外 80,000 股 E 系列优先股（面值最多 200 万美元），这取决于在未来 12 到 24 个月内实现某些收入和现金回收里程碑。预计在满足多项成交条件后尽快完成交易，包括但不限于尽职调查的完成和认股权证及雇佣协议的最终确定。此外，FOXO 已同意为 Vector 的增长计划提供最多 120 万美元的资金。有关 Vector Biosource 的信息可以在 www.vectorbiosource.com 找到。</p>
</div><p>“We are pleased to have reached agreement with Vector to move forward with this strategic acquisition,” said Seamus Lagan, Chief Executive Officer of FOXO. “We are attracted to Vector’s position in this sector of healthcare services, its business fundamentals and growth profile and intend to work closely with Vector senior leadership to aggressively expand Vector through organic growth and potentially acquisitions.” Frank Dias, Jr., CEO of Vector explained, “We believe the partnership with FOXO will allow Vector to achieve its near and long-term growth plans by providing growth capital, corporate infrastructure and potential synergies with other FOXO subsidiaries.”</p>
<div class="lb-trans"><p>“我们很高兴与 Vector 达成协议，推进这一战略收购，” FOXO 首席执行官 Seamus Lagan 表示。“我们被 Vector 在医疗服务领域的地位、其商业基本面和增长前景所吸引，并打算与 Vector 的高级领导层紧密合作，通过有机增长和潜在收购积极扩展 Vector。” Vector 的首席执行官 Frank Dias, Jr.解释道：“我们相信与 FOXO 的合作将使 Vector 能够通过提供增长资金、企业基础设施和与其他 FOXO 子公司的潜在协同效应，实现其近期和长期的增长计划。”</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (&#34;Securities Act&#34;). This announcement is being issued in accordance with Rule 135 under the Securities Act.</p>
<div class="lb-trans"><p>本新闻稿不构成出售任何证券的要约或购买任何证券的要约邀请。任何要约、购买要约的邀请或任何证券的销售将根据《1933 年证券法》（修订版）（“证券法”）的注册要求进行。本公告是根据证券法第 135 条发布的。</p>
</div><p><strong>AboutFOXO Technologies Inc.(“FOXO”)</strong></p>
<div class="lb-trans"><p><strong>关于 FOXO Technologies Inc.（“FOXO”）</strong></p>
</div><p>FOXOowns and operates three subsidiaries.</p>
<div class="lb-trans"><p>FOXO 拥有并运营三家子公司。</p>
</div><p>Rennova Community Health, Inc. owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital in East Tennessee.</p>
<div class="lb-trans"><p>Rennova Community Health, Inc.拥有并运营 Scott County Community Hospital, Inc.（以 Big South Fork Medical Center 为名），这是位于东田纳西州的一家关键接入医院（CAH）。</p>
</div><p>Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.</p>
<div class="lb-trans"><p>Myrtle Recovery Centers, Inc.是一家位于东田纳西州的 30 床位行为健康设施。Myrtle 提供住院戒毒和住院治疗服务，以及 MAT 和 OBOT 项目的门诊服务。</p>
</div><p>FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.</p>
<div class="lb-trans"><p>FOXO Labs, Inc.是一家生物技术公司，致力于通过开发尖端技术和产品解决方案来改善人类健康和寿命，服务于各个行业。</p>
</div><p>For more information aboutFOXO, visitwww.foxotechnologies.com.</p>
<div class="lb-trans"><p>有关 FOXO 的更多信息，请访问 www.foxotechnologies.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。这些声明是在 1995 年美国私人证券诉讼改革法的 “安全港” 条款下作出的。非历史事实的声明，包括关于 FOXO 的信念和期望的声明，均为前瞻性声明。前瞻性声明涉及固有的风险和不确定性，许多因素可能导致实际结果与任何前瞻性声明中包含的结果有重大差异。这些因素包括但不限于 FOXO 所处的竞争激烈且高度监管的行业中变化的风险；竞争对手之间的运营表现差异或影响 FOXO 业务的法律法规变化；实施 FOXO 的商业计划、预测和其他期望的能力；获得融资的能力；FOXO 有亏损历史，未来可能无法实现或维持盈利的风险；FOXO 的知识产权的可执行性，包括其专利，以及可能侵犯他人知识产权的风险；以及 FOXO 所处的高度竞争行业中经济下滑和监管环境变化的风险。上述因素的清单并不详尽。读者应仔细考虑上述因素以及 FOXO 最近在 10-K 和 10-Q 表格中讨论的其他风险和不确定性，特别是这些报告的 “风险因素” 部分，以及 FOXO 已提交或将提交给 SEC 的其他文件。这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有重大差异的其他重要风险和不确定性。前瞻性声明仅在作出之日有效。读者被警告不要过度依赖前瞻性声明，FOXO 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Sebastien Sainsbury</p>
<div class="lb-trans"><p>Sebastien Sainsbury</p>
</div><p>ssainsbury@foxotechnologies.com</p>
<div class="lb-trans"><p>ssainsbury@foxotechnologies.com</p>
</div><p>(561) 485-0151</p>
<div class="lb-trans"><p>(561) 485-0151</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeU56RTBNQ00zTVRReE5EazNJelV3TURFeU9UQXpNUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUyNzE0MCM3MTQxNDk3IzUwMDEyOTAzMQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NDI0OGFjMzEtMDBiNC00YjFiLWEyMTMtODg1NTU4ZDdmMTRmLTUwMDEyOTAzMS0yMDI1LTA5LTExLWVu/tiny/FOXO-Technologies-Inc-.png"/></p>

FOXO 科技公司宣布达成收购协议，将收购 Vector Biosource 公司 | FOXO 股票新闻